Opinion|Videos|November 4, 2024
Complement Inhibitors for Treatment of Generalized Myasthenia Gravis
Panelists discuss how complement inhibitors work to treat generalized myasthenia gravis (gMG), evaluating their efficacy and safety profiles based on FDA approvals and clinical experience.
Advertisement
Video content above is prompted by the following:
- Complement inhibitor agents have been approved by the FDA for treatment of gMG. Provide an overview of their mechanism of action and your overall impressions of the efficacy and safety of these agents.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- Expanding the Alzheimer Drug Development Pipeline
September 12th 2025
- Setting Realistic Expectations for Antiamyloid Therapeutics
September 11th 2025
- Monitoring and Managing ARIA in Antiamyloid Treatments
September 10th 2025
- 2025 LGS Meeting Reflections and Engagement Opportunities in Research
September 8th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
Expanding the Alzheimer Drug Development Pipeline
3
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
4
NeurologyLive® Friday 5 — September 12, 2025
5